Percepções da psicologia hospitalar diante à pandemia da COVID-19: considerações sobre o impacto social e a atuação na rede de saúde : Perceptions of hospital psychology in the face of the COVID-19 pandemic: considerations about the social impact and the performance in the health network

O atual contexto da pandemia da Covid-19 torna emergente a interpretação e adequação da atividade profissional dentro da situação de crise, com fim de dar conta da demanda. Em virtude disso, os profissionais da saúde interpretam o contexto em pauta para a atuação profissional, já que uma situação de crise comportamental e de saúde é, incontestavelmente, um fator prejudicial e comprometedor para a saúde mental da população. Com ênfase na atuação do profissional psicólogo e como ela se desenvolve em equipe hospitalar, se demarca a Psicologia Hospitalar como esfera central, já que engloba a realidade da crise de saúde e sanitária. Dessa forma, se objetivou a realização de uma pesquisa de caráter qualitativo por meio de entrevistas com psicólogos e profissionais da equipe de saúde de hospitais gerais situados no Sertão Central-CE. A coleta de dados se deu por meio da participação de 11 trabalhadores da saúde, tornando possível explorar as condições e impactos enfrentados pela sociedade sob a perspectiva da rede de atenção. Com isso, foi possível a observação de uma atuação multiprofissional construída nos campos de coleta, onde houve uma perceptível demanda hospitalar voltada ao atendimento de casos de sofrimento e fenômenos decorrentes diretamente da pandemia e suas consequências. Grandes fatores ansiogênicos foram notados, como as demandas de crise percebidas na população. Em virtude dos fatos supracitados, foi observado que houve um aumento perceptível entre os pacientes dos serviços em foco que procuravam atendimento hospitalar por sofrimento psíquico, modificando os eixos de manejo da Psicologia que precisou se moldar ao contexto de crise

Planta de producció d'òxid d'etilè

S'ha dissenyat i s'ha estudiat la viabilitat d'una planta química per la producció en continu d'òxid d'etilè a partir d'oxigen i etilè. La planta, situada a la Canonja, Tarragona, s'ha dimensionat per una producció de 120.000 T/any. El procés consta de tres etapes: la reacció de l'òxid d'etilè, la purificació d'aquest i la separació de diòxid de carboni de la resta de gasos. El control automàtic i la seguretat industrial són aspectes clau del projecte

A chemical survey of exoplanets with ARIEL

Thousands of exoplanets have now been discovered with a huge range of masses, sizes and orbits: from rocky Earth-like planets to large gas giants grazing the surface of their host star. However, the essential nature of these exoplanets remains largely mysterious: there is no known, discernible pattern linking the presence, size, or orbital parameters of a planet to the nature of its parent star. We have little idea whether the chemistry of a planet is linked to its formation environment, or whether the type of host star drives the physics and chemistry of the planet’s birth, and evolution. ARIEL was conceived to observe a large number (~1000) of transiting planets for statistical understanding, including gas giants, Neptunes, super-Earths and Earth-size planets around a range of host star types using transit spectroscopy in the 1.25–7.8 μm spectral range and multiple narrow-band photometry in the optical. ARIEL will focus on warm and hot planets to take advantage of their well-mixed atmospheres which should show minimal condensation and sequestration of high-Z materials compared to their colder Solar System siblings. Said warm and hot atmospheres are expected to be more representative of the planetary bulk composition. Observations of these warm/hot exoplanets, and in particular of their elemental composition (especially C, O, N, S, Si), will allow the understanding of the early stages of planetary and atmospheric formation during the nebular phase and the following few million years. ARIEL will thus provide a representative picture of the chemical nature of the exoplanets and relate this directly to the type and chemical environment of the host star. ARIEL is designed as a dedicated survey mission for combined-light spectroscopy, capable of observing a large and well-defined planet sample within its 4-year mission lifetime. Transit, eclipse and phase-curve spectroscopy methods, whereby the signal from the star and planet are differentiated using knowledge of the planetary ephemerides, allow us to measure atmospheric signals from the planet at levels of 10–100 part per million (ppm) relative to the star and, given the bright nature of targets, also allows more sophisticated techniques, such as eclipse mapping, to give a deeper insight into the nature of the atmosphere. These types of observations require a stable payload and satellite platform with broad, instantaneous wavelength coverage to detect many molecular species, probe the thermal structure, identify clouds and monitor the stellar activity. The wavelength range proposed covers all the expected major atmospheric gases from e.g. H2O, CO2, CH4 NH3, HCN, H2S through to the more exotic metallic compounds, such as TiO, VO, and condensed species. Simulations of ARIEL performance in conducting exoplanet surveys have been performed – using conservative estimates of mission performance and a full model of all significant noise sources in the measurement – using a list of potential ARIEL targets that incorporates the latest available exoplanet statistics. The conclusion at the end of the Phase A study, is that ARIEL – in line with the stated mission objectives – will be able to observe about 1000 exoplanets depending on the details of the adopted survey strategy, thus confirming the feasibility of the main science objectives.Peer reviewedFinal Published versio

Different epidemiology of bloodstream infections in COVID-19 compared to non-COVID-19 critically ill patients: A descriptive analysis of the Eurobact II study

Background: The study aimed to describe the epidemiology and outcomes of hospital-acquired bloodstream infections (HABSIs) between COVID-19 and non-COVID-19 critically ill patients. Methods: We used data from the Eurobact II study, a prospective observational multicontinental cohort study on HABSI treated in ICU. For the current analysis, we selected centers that included both COVID-19 and non-COVID-19 critically ill patients. We performed descriptive statistics between COVID-19 and non-COVID-19 in terms of patients’ characteristics, source of infection and microorganism distribution. We studied the association between COVID-19 status and mortality using multivariable fragility Cox models. Results: A total of 53 centers from 19 countries over the 5 continents were eligible. Overall, 829 patients (median age 65 years [IQR 55; 74]; male, n = 538 [64.9%]) were treated for a HABSI. Included patients comprised 252 (30.4%) COVID-19 and 577 (69.6%) non-COVID-19 patients. The time interval between hospital admission and HABSI was similar between both groups. Respiratory sources (40.1 vs. 26.0%, p < 0.0001) and primary HABSI (25.4% vs. 17.2%, p = 0.006) were more frequent in COVID-19 patients. COVID-19 patients had more often enterococcal (20.5% vs. 9%) and Acinetobacter spp. (18.8% vs. 13.6%) HABSIs. Bacteremic COVID-19 patients had an increased mortality hazard ratio (HR) versus non-COVID-19 patients (HR 1.91, 95% CI 1.49–2.45). Conclusions: We showed that the epidemiology of HABSI differed between COVID-19 and non-COVID-19 patients. Enterococcal HABSI predominated in COVID-19 patients. COVID-19 patients with HABSI had elevated risk of mortality. Trial registration ClinicalTrials.org number NCT03937245. Registered 3 May 2019

Transverse momentum spectra of b jets in pPb collisions at sqrt(s[NN]) = 5.02 TeV

We present a measurement of b jet transverse momentum (pt) spectra in proton-lead (pPb) collisions using a dataset corresponding to about 35 inverse nanobarns collected with the CMS detector at the LHC. Jets from b quark fragmentation are found by exploiting the long lifetime of hadrons containing a b quark through tagging methods using distributions of the secondary vertex mass and displacement. Extracted cross sections for b jets are scaled by the effective number of nucleon-nucleon collisions and are compared to a reference obtained from PYTHIA simulations of pp collisions. The PYTHIA-based estimate of the nuclear modification factor is found to be 1.22 +/- 0.15 (stat + syst pPb) +/- 0.27 (syst PYTHIA) averaged over all jets with pt between 55 and 400 GeV/c and with abs(eta[lab]) < 2. We also compare this result to predictions from models using perturbative calculations in quantum chromodynamics

ECMO for COVID-19 patients in Europe and Israel

Since March 15th, 2020, 177 centres from Europe and Israel have joined the study, routinely reporting on the ECMO support they provide to COVID-19 patients. The mean annual number of cases treated with ECMO in the participating centres before the pandemic (2019) was 55. The number of COVID-19 patients has increased rapidly each week reaching 1531 treated patients as of September 14th. The greatest number of cases has been reported from France (n = 385), UK (n = 193), Germany (n = 176), Spain (n = 166), and Italy (n = 136) .The mean age of treated patients was 52.6 years (range 16–80), 79% were male. The ECMO configuration used was VV in 91% of cases, VA in 5% and other in 4%. The mean PaO2 before ECMO implantation was 65 mmHg. The mean duration of ECMO support thus far has been 18 days and the mean ICU length of stay of these patients was 33 days. As of the 14th September, overall 841 patients have been weaned from ECMO support, 601 died during ECMO support, 71 died after withdrawal of ECMO, 79 are still receiving ECMO support and for 10 patients status n.a. . Our preliminary data suggest that patients placed on ECMO with severe refractory respiratory or cardiac failure secondary to COVID-19 have a reasonable (55%) chance of survival. Further extensive data analysis is expected to provide invaluable information on the demographics, severity of illness, indications and different ECMO management strategies in these patients

Multi-ancestry sleep-by-SNP interaction analysis in 126,926 individuals reveals lipid loci stratified by sleep duration.

Both short and long sleep are associated with an adverse lipid profile, likely through different biological pathways. To elucidate the biology of sleep-associated adverse lipid profile, we conduct multi-ancestry genome-wide sleep-SNP interaction analyses on three lipid traits (HDL-c, LDL-c and triglycerides). In the total study sample (discovery + replication) of 126,926 individuals from 5 different ancestry groups, when considering either long or short total sleep time interactions in joint analyses, we identify 49 previously unreported lipid loci, and 10 additional previously unreported lipid loci in a restricted sample of European-ancestry cohorts. In addition, we identify new gene-sleep interactions for known lipid loci such as LPL and PCSK9. The previously unreported lipid loci have a modest explained variance in lipid levels: most notable, gene-short-sleep interactions explain 4.25% of the variance in triglyceride level. Collectively, these findings contribute to our understanding of the biological mechanisms involved in sleep-associated adverse lipid profiles

Measurement of differential cross sections for top quark pair production using the lepton plus jets final state in proton-proton collisions at 13 TeV

National Science Foundation (U.S.